Accelerate Antibody Development And Production

MaxCyte’s electroporation platform revolutionizes antibody development by enabling rapid, scalable transfection for transient and stable protein expression. Its advanced technology facilitates the production of therapeutic antibodies with unmatched efficiency, from discovery to commercial manufacturing.

The platform supports transient expression to generate gram-scale protein yields within weeks, significantly reducing timelines compared to traditional methods. Transient expression delivers high-quality protein for IND-enabling studies, allowing faster evaluation of antibody efficacy and toxicology. MaxCyte’s system eliminates the need for revalidation when transitioning to manufacturing cell lines, ensuring continuity and reducing the risk of candidate failure.

For stable cell line development, MaxCyte’s high transfection efficiency and cell viability accelerate workflows. Electroporated cells recover from selection faster, enabling researchers to identify high-yielding clones in under eight weeks. The platform also supports stable bulk pool development, an efficient alternative for early clinical studies.

Scalability is a core feature of MaxCyte’s platform, with the ability to transfect 75,000 to over 100 billion cells using their Flow Electroporation^® technology. Researchers can seamlessly scale processes from small to large volumes without re-optimization, saving time and resources.

MaxCyte also ensures flexibility, allowing users to transfect any cell type and express a wide range of proteins, including novel antibody formats. The platform’s integrated tools and robust performance streamline antibody discovery, development, and manufacturing, empowering researchers to bring innovative therapies to patients faster.

MaxCyte provides a comprehensive solution for accelerating antibody development while reducing costs and improving efficiency.